Table 2 Major bleeding details and type of anticoagulant therapy reported by studies included in this meta-analysis
References | Group of treatment (No. of bleeding patients) | Number of events and the site of major bleeding | ||||||
|---|---|---|---|---|---|---|---|---|
Upper GI tract | Lower GI tract | Central nervous system | Genitourinary tract | Retroperitoneal area | Intra-abdominal area | Other sites | ||
Kraaipoel et al. 2018 [30] | Edoxaban (21) | 16 | 3 | - | - | 1 | - | 1 Epistaxis |
Dalteparin (5) | 1 | - | 2 intracerebral hemorrhage 1 thoracic spinal cord | - | - | - | 1 Not mentioned | |
Kim et al. 2020 [22] | Rivaroxaban (12) | 7 | 2 | - | - | - | - | 3 Unspecified GI tract |
LMWHs (8) | 2 | 1 | - | - | - | 3 hemoperitoneum | 1 Unspecified GI tract 1 Unspecified site | |
Ageno et al. 2020 [24] | Apixaban (9) | 4 | 3 | - | 1 | - | 1 | Â |
Dalteparin (9) | 3 | 3 | - | - | 1 | - | 2 Upper airway 1 Muscle | |
Kim et al. 2022 [29] | Apixaban or Rivaroxaban (6) | 6 | 1 | - | - | - | 1 Vaginal | |
Dalteparin (2) | 2 | - | - | - | - | Â | ||